Infiuss Health
Democratizing Access to Clinical Research

Decentralized trials are the future of clinical research, with the potential to improve diversity, accessibility, and retention. A majority of life sciences companies in the U.S. are looking to diversify their clinical studies by exploring previously excluded regions like Africa, a potential clinical trial powerhouse with one of the most genetically diverse populations in the world. It will greatly improve research outcomes and ensure health equity across populations with a higher disease burden.

But as the traditional clinical research infrastructure is centralized, which requires patients to go to sites, how do organizations transition their existing clinical studies and manage them across remote, diverse geographies?

Infiuss Health’s end-to-end, first-of-its-kind, clinical trial management platform is the answer.

“Our mission is to bring clinical trials to populations that have previously not been included in or allowed fair participation in these breakthrough studies,” says Melissa Bime, CEO of Infiuss Health. “By doing so, we believe this inherently solves one of the problems pharma struggles with currently, which is that of accessing more diverse and heterogeneous populations, giving them the ability to make therapies that are applicable to broader population bases.”

Infiuss has built a dual system that combines a sponsor-facing platform, backed by a site administrator that helps manage both the site and the patient. The platform’s simple interface gives sponsors the comfort and flexibility to conduct studies in Africa from anywhere in the world. It takes a detailed account of the type of study the sponsors want to run and their eligibility criteria. The platform is highly modular, allowing clients to choose the options applicable to each study.

After working on a sponsor’s needs on the platform, the Infiuss team goes into the field and implements the study with the participants, collecting the data and feeding it back to the platform in line with the sponsor’s requests.

Focused primarily on populations outside of the U.S. or Europe, Infiuss has grown a vast network of sites, primary investigators, and patients to meet the specific needs of sponsors on its platform. The network allows it to connect with a study’s participants and conceptualize within disparate environments.

While addressing the needs of different populations and helping life sciences companies navigate those spaces, Infiuss simultaneously maintains the ability to conduct excellent clinical studies and collects high-quality data to increase generalizability in clinical trials. Its study-specific and highly flexible solutions allow sponsors to conduct their choice of fully remote or hybrid clinical research studies.

Infiuss is reinventing the wheel of clinical research in the fragmented space of clinical trial management. Despite an influx of high-end technologies and newly proposed approaches, clinical trial management companies struggle with the inability to provide a good experience for the patients and participants. Knowing that no two clients are the same, the Infiuss team closely examines every client need to create a great clinical trial management experience, from the technology and staff to study participants.

Infiuss focuses on a variety of indications, including infectious and rare diseases, hematology, maternal health, and major tropical diseases. Substantiating its capabilities is an instance where a UK-based client sought to conduct a human biological collection study that was originally designated to last ten weeks. Understanding and prioritizing the client’s needs and tapping into its network allowed Infiuss to quickly identify the best way to meet those needs. The client was able to complete the study in two weeks.

Another study involved a sponsor who wanted the ability to talk to and collect data from patients suffering from postpartum hemorrhage. Infiuss onboarded the sponsor within two hours and collected all the information to understand its requirements. It tapped into its extensive network to determine a way to deliver on the client’s needs, and completed the study across four countries within two weeks.

Sponsors that seek to run clinical studies from anywhere, who want to expedite their research and manage their sites and peers from one place can rely on Infiuss’ decentralized clinical trial platform.